Literature DB >> 661889

Urinary kallikrein activity in the hypertension of renal parenchymal disease.

J A Mitas, S B Levy, R Holle, R P Frigon, R A Stone.   

Abstract

To learn more about the regulation of blood pressure in renal parenchymal disease, 57 subjects (18 normal controls, 25 patients with essential hypertension and 14 with renal parenchymal disease and hypertension) were evaluated for peripheral renin activity, 24-hour urinary kallikrein activity and whole-blood volume. Blood volumes were significantly lower in patients with essential hypertension (P less than 0.001) and those with renal disease and hypertension (P less than 0.001) than in normotensive subjects. Renin activities (measured after the subjects were standing) were also lower in patients with essential hypertension and hypertension due to renal disease (P less than 0.01 and P less than 0.02, respectively). Kallikrein activity was similar in subjects with renal disease and those with hypertension (P less than 0.05) but markedly diminished in both groups as compared with normotensive subjects (P less than 0.001 and P less than 0.01, respectively) when glomerular filtration rates were taken into account. The kallikrein-kinin system may be involved in the hypertension associated with renal parenchymal disease.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 661889     DOI: 10.1056/NEJM197807272990402

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  9 in total

1.  Role of urinary alpha1-antitrypsin in Padutin (kallikrein) inactivation.

Authors:  W H Hörl; R M Schäfer; A Heidland
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

2.  Plasma renin activity and urinary kallikrein excretion in response to intravenous furosemide in diabetic patients.

Authors:  S B Lall; S Kunchaparty; H H Siddiqui; J S Bajaj
Journal:  Acta Diabetol Lat       Date:  1990 Oct-Dec

Review 3.  [Prostaglandins in cardiovascular and renal function. Biochemical, physiological and clinical findings (author's transl)].

Authors:  P C Weber; W Siess; B Scherer
Journal:  Klin Wochenschr       Date:  1979-05-03

4.  Localization of kallikrein-like activity along a single nephron in rabbits.

Authors:  K Tomita; H Endou; F Sakai
Journal:  Pflugers Arch       Date:  1981-01       Impact factor: 3.657

5.  Renal kallikrein in diabetic patients with hypertension accompanied by nephropathy.

Authors:  T Baba; S Murabayashi; T Ishizaki; Y Ido; K Aoyagi; K Takebe
Journal:  Diabetologia       Date:  1986-03       Impact factor: 10.122

6.  Tissue kallikrein synthesis and its modification by testosterone or low dietary sodium.

Authors:  D H Miller; J Chao; H S Margolius
Journal:  Biochem J       Date:  1984-02-15       Impact factor: 3.857

7.  Urinary kallikrein excretion in essential and mineralocorticoid hypertension.

Authors:  O B Holland; J M Chud; H Braunstein
Journal:  J Clin Invest       Date:  1980-02       Impact factor: 14.808

8.  Antihypertensive mechanism of the diuretic muzolimine in mild renal failure. Roles of sodium and cardiovascular norepinephrine responsiveness.

Authors:  H Schiffl; P Weidmann; C Beretta-Piccoli; C Cottier; A J Seiler; W H Ziegler
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

9.  Hypertension in chronic kidney disease: navigating the evidence.

Authors:  F M Tedla; A Brar; R Browne; C Brown
Journal:  Int J Hypertens       Date:  2011-05-24       Impact factor: 2.420

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.